



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration
Rockville, MD 20857

NDA 18-422/S-045

Pfizer Pharmaceuticals Limited
Pfizer Inc., U. S. Agent
Attention: Robert B. Clark
Vice President, U.S. Regulatory
235 East 42nd Street
New York, NY 10017

Dear Mr. Clark:

Please refer to your supplemental new drug application dated December 18, 2003, received December 19, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lopid (gemfibrozil) Tablets.

We acknowledge receipt of your submission dated March 15, 2004.

This supplemental new drug application provides for the revision of the package insert to include information regarding repaglinide under the **PRECAUTIONS** section of the package insert.

To the **PRECAUTIONS, Drug Interactions** subsection, a new paragraph has been added:

“(C) Repaglinide: In vivo data from a study that evaluated the co-administration of gemfibrozil with repaglinide in healthy subjects resulted in a significant increase in repaglinide blood levels. Patients taking repaglinide should not start taking gemfibrozil; patients taking gemfibrozil should not start taking repaglinide. Concomitant use may result in enhanced and prolonged blood glucose-lowering effects of repaglinide. Caution should be used in patients already on repaglinide and gemfibrozil- blood glucose levels should be monitored and repaglinide dose adjustment may be needed. Rare post marketing events of serious hypoglycemia have been reported in patients taking repaglinide and gemfibrozil together. In this same study, gemfibrozil and itraconazole had a synergistic metabolic inhibitory effect on repaglinide. Therefore, patients taking repaglinide and gemfibrozil should not take itraconazole.”

We completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted March 15, 2004).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL

as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 18-422/S-045." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Valerie Jimenez, Regulatory Project Manager, at (301) 827-9090.

Sincerely,

{See appended electronic signature page}

David Orloff, M. D.
Director
Division of Metabolic and Endocrine Drug
Products
Office of New Drug II
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

David Orloff

3/30/04 01:00:02 PM